StockData
Humacyte, Inc. logo

Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30
$0.50−0.04 (-7.27%)

Close on Nov 17, 2026Market cap $139.18MP/E –Yield –

Humacyte pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Humacyte's pe ratio was 7.9× on Jan 31, 2023.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Jan 31, 20237.9×+1.6
2022Dec 30, 20226.3×–

More Humacyte figures

See a number that looks wrong?